Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer
about
shRNA-armed conditionally replicative adenoviruses: a promising approach for cancer therapyOncolytic adenovirus-mediated therapy for prostate cancerTrial Watch-Oncolytic viruses and cancer therapyOncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future PerspectivesGene Therapy 2017: Progress and Future Directions.In situ immunization via non-surgical ablation to prevent local and distant tumor recurrence.Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors.Arg-Gly-Asp (RGD)-Modified E1A/E1B Double Mutant Adenovirus Enhances Antitumor Activity in Prostate Cancer Cells In Vitro and in MiceUSE OF PATIENT ASSESSED HEALTH-RELATED QUALITY OF LIFE INSTRUMENTS IN PROSTATE CANCER RESEARCH: A SYSTEMATIC REVIEW OF THE LITERATURE 2002-15.Polymeric oncolytic adenovirus for cancer gene therapy.Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues.Combining Oncolytic Adenovirus with Radiation-A Paradigm for the Future of Radiosensitization.Oncolytic virotherapy for urological cancers.Preclinical toxicology of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for prostate cancer.Prostate cancer: viral gene therapy can improve IMRT.Ki67 targeted strategies for cancer therapy.Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma.Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus Ad∆∆ through Bcl-2-dependent attenuation of autophagy.Designer Oncolytic Adenovirus: Coming of Age.Astragaloside attenuates the progression of prostate cancer cells through endoplasmic reticulum stress pathways
P2860
Q26765364-58AD7F1A-1E33-4E05-A15C-51DBC16437CFQ27004796-35CD490E-6610-497F-9C00-7289566BA3A4Q28072347-293C27DB-8D82-40AD-A9DF-A3076C782B40Q33679505-87507AA1-93D8-423B-ACB3-8DDB8F7BB8A6Q33891559-D7AFCDE9-6126-4801-B184-5C89D85D4C41Q34475389-6C79B414-F205-4682-A786-DE8CA9A634F2Q35201826-DC415467-2623-4B79-B655-59CEDD6225BAQ35901283-4387CC87-74C9-46CA-B9AF-645D19F6564DQ35965515-CCB3678A-D326-430E-A9D6-E59FB36F91FDQ36344901-B5B2BEC6-A31C-443F-A66B-18533D548D2DQ36757131-65BB29C6-1225-444C-8F3E-EEDFD5939413Q38645128-19AEC173-27E1-4BAE-B167-5BFACC691F6AQ38842126-49162EDA-3769-4862-A7D3-1510A3921061Q38920828-7DE8673A-9547-43C5-8F7D-5B8775972287Q42212189-EB5073A0-0516-4163-B31C-F8836968FDA4Q45873470-21811370-6925-4BB3-B857-042DEC0E5323Q47141309-25BE06EF-9F3E-471B-AB2F-FB2A5C1E12D4Q47549552-6001520A-1F8E-4F01-B482-4DAA35E95A80Q55467684-A0FC5219-0650-4743-B176-F84BFF138E79Q57165697-39256FCF-74D7-4E2E-BA6A-0367C15B9944
P2860
Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Prospective randomized phase 2 ...... ermediate-risk prostate cancer
@ast
Prospective randomized phase 2 ...... ermediate-risk prostate cancer
@en
type
label
Prospective randomized phase 2 ...... ermediate-risk prostate cancer
@ast
Prospective randomized phase 2 ...... ermediate-risk prostate cancer
@en
prefLabel
Prospective randomized phase 2 ...... ermediate-risk prostate cancer
@ast
Prospective randomized phase 2 ...... ermediate-risk prostate cancer
@en
P2093
P2860
P921
P1476
Prospective randomized phase 2 ...... ermediate-risk prostate cancer
@en
P2093
Benjamin Movsas
Farzan Siddiqui
Hans Stricker
Ibrahim Aref
Jae Ho Kim
James Peabody
Jingfang Cheng
Kenneth Barton
Kenneth Levin
P2860
P304
P356
10.1016/J.IJROBP.2014.02.034
P407
P577
2014-05-05T00:00:00Z